Krystal Biotech (NASDAQ:KRYS) Sets New 12-Month High – Here’s Why

Krystal Biotech, Inc. (NASDAQ:KRYS)’s stock price hit a new 52-week high during mid-day trading on Friday . The company traded as high as $213.69 and last traded at $212.6640, with a volume of 137363 shares trading hands. The stock had previously closed at $204.23.

Analyst Upgrades and Downgrades

KRYS has been the subject of several recent analyst reports. Guggenheim set a $224.00 target price on Krystal Biotech and gave the stock a “buy” rating in a research note on Friday, October 17th. HC Wainwright restated a “buy” rating and set a $240.00 price target on shares of Krystal Biotech in a report on Monday, September 15th. Chardan Capital raised their price objective on shares of Krystal Biotech from $216.00 to $220.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Bank of America lifted their price objective on shares of Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Krystal Biotech in a research note on Wednesday. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $228.14.

Krystal Biotech Price Performance

The firm has a market cap of $6.17 billion, a P/E ratio of 31.89 and a beta of 0.65. The company has a fifty day moving average of $184.93 and a 200-day moving average of $156.29.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $1.54. The firm had revenue of $97.80 million for the quarter, compared to the consensus estimate of $93.72 million. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. On average, sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Institutional Trading of Krystal Biotech

A number of institutional investors and hedge funds have recently modified their holdings of the business. Avoro Capital Advisors LLC increased its position in shares of Krystal Biotech by 4.4% during the 3rd quarter. Avoro Capital Advisors LLC now owns 2,777,777 shares of the company’s stock valued at $490,361,000 after purchasing an additional 117,777 shares during the last quarter. State Street Corp raised its holdings in shares of Krystal Biotech by 10.5% in the 2nd quarter. State Street Corp now owns 1,355,346 shares of the company’s stock worth $186,306,000 after purchasing an additional 128,639 shares during the period. Soleus Capital Management L.P. lifted its stake in Krystal Biotech by 108.9% in the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after purchasing an additional 481,200 shares during the last quarter. Braidwell LP grew its holdings in Krystal Biotech by 81.6% during the second quarter. Braidwell LP now owns 727,811 shares of the company’s stock valued at $100,045,000 after purchasing an additional 327,067 shares during the period. Finally, Geode Capital Management LLC increased its position in Krystal Biotech by 1.2% in the second quarter. Geode Capital Management LLC now owns 619,547 shares of the company’s stock worth $85,174,000 after buying an additional 7,194 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).